1 research outputs found

    PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

    No full text
    Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug
    corecore